Presentation Title

Profiling the microbiome in pancreatic ductal adenocarcinoma

Advisor Information

Dr. Cooper

Location

MBSC Ballroom - Poster #501 - U

Presentation Type

Poster

Start Date

4-3-2022 9:00 AM

End Date

4-3-2022 10:15 AM

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is currently the fourth-most diagnosed cancer in the world. The gut microbiome is key to understanding PDAC. The microbiome has shown to undergo changes during the course of treatment, often interfering with the efficacy of various treatments. These changes have led researchers to investigate how the microbiome may be targeted as a treatment approach. This project explores currently available datasets for and reviews the current research investigating whether specific microbiome profiles are associated with particular cancer phenotypes. Results of this project will inform future research on drug-related temporal changes of the microbiome, which can be leveraged to predict treatment response and refine treatment approaches in treatment-resistant sub-types..

Creative Commons License

Creative Commons Attribution 4.0 License
This work is licensed under a Creative Commons Attribution 4.0 License.

This document is currently not available here.

COinS
 
Mar 4th, 9:00 AM Mar 4th, 10:15 AM

Profiling the microbiome in pancreatic ductal adenocarcinoma

MBSC Ballroom - Poster #501 - U

Pancreatic ductal adenocarcinoma (PDAC) is currently the fourth-most diagnosed cancer in the world. The gut microbiome is key to understanding PDAC. The microbiome has shown to undergo changes during the course of treatment, often interfering with the efficacy of various treatments. These changes have led researchers to investigate how the microbiome may be targeted as a treatment approach. This project explores currently available datasets for and reviews the current research investigating whether specific microbiome profiles are associated with particular cancer phenotypes. Results of this project will inform future research on drug-related temporal changes of the microbiome, which can be leveraged to predict treatment response and refine treatment approaches in treatment-resistant sub-types..